Nivolumab in the CheckMate 374, CheckMate 016, and CheckMate 025 Trials

摘要

Several posters presented findings from studies that evaluated nivolumab in various settings. The open-label, phase 3b/4 CheckMate 374 study evaluated nivolumab in 3 cohorts of patients with advanced or metastatic RCC: those with clear cell RCC, those with non-clear cell RCC, and those with brain metastases.1 Treatment consisted of intravenous nivolumab (240 mg) every 2 weeks. The study included 98 patients with clear cell RCC, 43 patients with non-clear cell RCC, and 1 patient with brain metastases. Nearly all of the patients (99%) with clear cell RCC had received at least 1 prior systemic therapy for their advanced disease, whereas the majority of non-clear cell RCC patients (65%) were treatment-naive. After a median follow-up of 8.0 months, the primary reason for treatment discontinuation was disease progression. Discontinuations owing to nivolumab toxicity occurred in 9 patients (9%) with clear cell RCC and 2 patients (5%) with non-clear cell RCC. The median duration of exposure was 5.1 months for patients with clear cell RCC and 3.3 months for patients with non-clear cell RCC.